spacer
home > ebr > summer 2017 > qbd in action
PUBLICATIONS
European Biopharmaceutical Review

QbD in Action

Humans are living increasingly longer due to continuous delivery of new chemical and biological entities (NBEs) from the pharmaceutical industry as tested and approved drugs. Unfortunately, this does not necessarily mean we are living healthier lives. With preventable issues on the rise – such as obesity, where 13% of the world’s adult population are now classed as overweight, or our dependency upon antibiotics giving rise to antibiotic resistance – some will debate this. However, there is a growing trend to deliver drugs that will contribute to a healthier society through the reduction of diseases, including cancer, cardiovascular disease, infectious diseases and neurological disorders, to name but a few.

NBEs are considerably more complex than traditional small molecule-based drugs due to their production by living cells and being hundreds of times larger and inherently more complicated to manufacture, so the existence of numerous regulatory guidelines is no surprise. These serve to ensure safety as well as efficacy and revolve around the continuous monitoring of key critical quality attributes (CQAs) throughout the drug development lifecycle. Routine characterisation can include observation of some of these CQAs through tests, such as charge variant profiling and aggregate analysis.

Recently, there has been a substantial focus on quality by design (QbD), with a joint pilot study by the EMA and FDA concluding that both agencies are well-aligned regarding the implementation of QbD concepts from ICH Q8, 9 and 10. They also stated that both agencies are “currently exploring potential joint activities with specific focus on continuous manufacturing, additional emerging technologies, and expedited/accelerated assessments”. The attention on utilising powerful detection techniques such as high-resolution mass spectrometry (MS) is growing within the chemistry, manufacturing and control stages through to quality control (QC) and lot release stages due to the increased levels of accuracy and information obtainable.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simon Cubbon is a Pharma and Biopharma Vertical Marketing Manager at Thermo Fisher Scientific. He has worked within the analytical instruments industry for over 10 years, holding a variety of positions, from applications scientist through to informatics product management. Simon studied for his PhD at the University of York, UK, where he investigated using LC-MS to study the metabolic profile of long bone fractures.
spacer
Simon Cubbon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Navigating the new Clinical Trial Regulation with DIA

For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will have a dramatic impact. The aim of the change in regulation is to increase the efficiency of all trials in Europe, as well as promoting research while avoiding the duplication of clinical trials
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

Drug Delivery Partnerships 2018

22-24 January 2018, PGA National Resort & Spa, Palm Beach Gardens, Florida

For 22 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement